drugset / Trial / NCT06107036

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

NCT06107036

Phase 1 Completed 46 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral administration on cardiac safety parameters in healthy male and female volunteers.

Timeline

Start
2024-03-06
Primary completion
2024-07-25
Completion
2024-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule Oral
Subject Nerandomilast Small molecule Oral

Indications

No indication recorded.